Home Cart Sign in  
Chemical Structure| 1357470-29-1 Chemical Structure| 1357470-29-1

Structure of Narazaciclib
CAS No.: 1357470-29-1

Chemical Structure| 1357470-29-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ON123300 is a potent and multi-targeted kinase inhibitor which inhibits CDK4, Ark5, PDGFRβ, FGFR1, RET, and Fyn with IC50 of 3.9 nM, 5 nM, 26 nM, 26 nM, 9.2 nM and 11nM respectively.

Synonyms: ON 123300; ON123300

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Narazaciclib

CAS No. :1357470-29-1
Formula : C24H27N7O
M.W : 429.52
SMILES Code : N#CC1=CC2=CN=C(NC3=CC=C(N4CCN(C)CC4)C=C3)N=C2N(C5CCCC5)C1=O
Synonyms :
ON 123300; ON123300
MDL No. :MFCD28411414
InChI Key :VADOZMZXXRBXNY-UHFFFAOYSA-N
Pubchem ID :56649281

Safety of Narazaciclib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Narazaciclib

Hedgehog

Isoform Comparison

Biological Activity

Target
  • FGFR1

    FGFR1, IC50:26 nM

  • CDK4

    CDK4/CyclinD1, IC50:3.87 nM

  • CDK6

    CDK6/CyclinD1, IC50:9.82 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Ba/F3-FLT3-ITD cells 95.32 nM Tested the inhibitory effect of Narazaciclib on the proliferation of Ba/F3-FLT3-ITD cells, showing potent inhibition. PMC11031590
M2-Macrophages 72.5 nM Tested the inhibitory effect of Narazaciclib on the proliferation of M2-Macrophages, showing potent inhibition. PMC11031590
Ba/F3-RBM6-CSF1R cells 36.94 nM Tested the inhibitory effect of Narazaciclib on the proliferation of Ba/F3-RBM6-CSF1R cells, showing potent inhibition. PMC11031590
Ba/F3-CSF1R cells 3.54 nM Tested the inhibitory effect of Narazaciclib on the proliferation of Ba/F3-CSF1R cells, showing potent inhibition. PMC11031590
Ba/F3-CSF1R cells 3.54 nM(IC50) To test the inhibitory effect of ON123300 on CSF1R-driven cell proliferation PMC11031590
GBM39 cells 4 μM Evaluate the effect of ON123300 on phosphorylation of Akt and Erk in GBM39 cells, showing 55% inhibition of Akt phosphorylation and 174% activation of Erk phosphorylation PMC4013241
U87 cells 6.3 μM 1 h Evaluate the inhibitory effect of ON123300 on phosphorylation of Akt and its downstream signaling molecules, showing decreased phosphorylation levels of Akt, P70S6K, rpS6, and Rb S780, while increased phosphorylation of Erk PMC4013241
U87 glioma cells 3.4 ± 0.1 μM(IC50) 72 h Evaluate the inhibitory effect of ON123300 on U87 glioma cell proliferation, showing an IC50 of 3.4 ± 0.1 μM PMC4013241
MEM2 (ibrutinib-resistant MCL) 500nM–5µM 24 h ON123300 induced apoptosis in both ibrutinib-sensitive and resistant MCL cells PMC4703501
MEM1 (ibrutinib-sensitive MCL) 500nM–5µM 24 h ON123300 induced apoptosis in both ibrutinib-sensitive and resistant MCL cells PMC4703501
Z138C 0.1–1.0µM(IC50) 24 h ON123300 induced G1 phase cell cycle arrest at lower concentrations and apoptosis at higher concentrations PMC4703501
Granta 519 0.1–1.0µM(IC50) 24 h ON123300 induced G1 phase cell cycle arrest at lower concentrations and apoptosis at higher concentrations PMC4703501
multiple myeloma cell lines EJM 50 nM 48 h To evaluate the antiproliferative effect of ON123300 on multiple myeloma cell lines, results showed that ON123300 significantly reduced cell viability at 50 nM concentration PMC5968814
multiple myeloma cell lines MM1.S 50 nM 48 h To evaluate the antiproliferative effect of ON123300 on multiple myeloma cell lines, results showed that ON123300 significantly reduced cell viability at 50 nM concentration PMC5968814
multiple myeloma cell lines NCI-H929 50 nM 48 h To evaluate the antiproliferative effect of ON123300 on multiple myeloma cell lines, results showed that ON123300 significantly reduced cell viability at 50 nM concentration PMC5968814
multiple myeloma cell lines MM.1R 50 nM 48 h To evaluate the antiproliferative effect of ON123300 on multiple myeloma cell lines, results showed that ON123300 significantly reduced cell viability at 50 nM concentration PMC5968814
Ba/F3-FLT3-ITD cells 95.32 nM(IC50) To test the inhibitory effect of ON123300 on FLT3-ITD-driven cell proliferation PMC11031590
M2 primary macrophages 72.5 nM(IC50) 7 days To test the inhibitory effect of ON123300 on M2 macrophage proliferation PMC11031590
Ba/F3-RBM6-CSF1R cells 36.94 nM(IC50) To test the inhibitory effect of ON123300 on RBM6-CSF1R fusion protein-driven cell proliferation PMC11031590

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice MV4-11 subcutaneous tumor model Intraperitoneal injection 100 mg/kg Twice per week for 3 weeks Tested the inhibitory effect of Narazaciclib on MV4-11 subcutaneous tumor growth, showing significant inhibition. PMC11031590
NIH Swiss nude mice U87 glioma model Intravenous injection 5 mg/kg and 25 mg/kg Single dose Evaluate the pharmacokinetic and pharmacodynamic properties of ON123300 in the U87 glioma model, showing high distribution of ON123300 in brain and brain tumor with a brain partition coefficient of at least 2.5. Single agent ON123300 caused dose-dependent suppression of Akt phosphorylation and activation of Erk, while addition of GFN significantly enhanced p-Akt inhibition and prevented Erk activation PMC4013241
CD-1 mice Z138C cell xenograft model Intraperitoneal injection 100mg/kg Daily or every alternate day for 14 days ON123300 significantly inhibited MCL tumor growth without obvious toxicity PMC4703501
NSG mice Multiple myeloma xenograft model Intraperitoneal injection 100 mg/kg Administered every alternate day until tumor diameter exceeded 1 cm or body weight loss exceeded 10% To evaluate the in vivo antitumor effect of ON123300 on multiple myeloma, results showed that ON123300 significantly inhibited tumor growth PMC5968814
NOD/scid mice MV4-11 subcutaneous tumor model Intraperitoneal injection 100 mg/kg Twice per week for 3 weeks To test the inhibitory effect of ON123300 on FLT3-ITD-driven AML tumor growth PMC11031590

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.33mL

0.47mL

0.23mL

11.64mL

2.33mL

1.16mL

23.28mL

4.66mL

2.33mL

References

 

Historical Records

Categories